New oral cancer drug enters first human safety trial
Disease control
Recruiting now
This early-stage study tests a new oral drug, AXT-1003, in 78 people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug shr…
Phase: PHASE1 • Sponsor: Axter Therapeutics (Beijing) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC